Pharma News, 2019

(Reuters) - The U.

(Reuters) - A U.

Officials with the FDA have approved Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL for the treatment of active ankylosing spondylitis (AS), also known as radiographic axial spond...

Purdue Pharma and the thousands of state and local governments suing the maker of OxyContin over the nation's deadly opioid crisis are negotiating a $10 billion to $12 billion settlement under whi...

Eli Lilly and Incyte have announced that Olumiant (baricitinib) met the primary endpoint in BREEZE-AD7, the third pivotal Phase III trial in the BREEZE-AD program to be completed in 2019.

Amgen agreed to buy Celgene’s Otezla, a treatment for psoriasis and Behçet’s disease, for $13.

(Reuters) - The U.

PLYMOUTH MEETING, PA, — Harmony Biosciences, LLC (Harmony) announced today that the U.

Sarepta Therapeutics was dealt a surprising setback Monday when the Food and Drug Administration rejected its marketing application for a second drug that aimed to treat children with Duchenne muscula...

On August 16, 2019, the Food and Drug Administration approved fedratinib (INREBIC, Impact Biomedicines, Inc.

TOKYO, Japan I July 30, 2019 I Eisai Co.

WHIPPANY, N.